Abstract
Lung cancer is one of the most fatal tumors at present. Although early lung cancer can be effectively intervened through surgery, the five-year survival rate is less than 55% because of its tendency for relapse and drug resistance. With the development of immunotherapy, such methods like activating the immune system and relieving immune tolerance have become the new direction in the systemic treatment of tumors. The newly discovered mechanism of immunostimulatory fatigue explains why immunotherapy is not very effective in some patients and finds that low-dose decitabine can relieve immunostimulatory fatigue. What’s more, radiotherapy has a significant effect on the killing of local tumors, then disintegrated tumor cells can release antigens and further activate the body’s immune system. Therefore, immunotherapy in combination with radiochemotherapy has shown great prospects of achieving efficacy on patients with lung cancer from systemic and local levels. This article describes the new progress of that method in treating lung cancer.